July 14, 2025

Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

Overall survival for patients treated with TP-0903 and decitabine was 7.6 months on average.
The median follow-up period for the trial participants was 9 months, providing insights into short-term outcomes.
Among 27 participants, responses included complete remission types such as CR, CRh, and CRi.
Findings suggest that targeting mutant TP53 and complex karyotype may be a promising strategy for older patients with acute myeloid leukemia.

Authors

EEEric D. EisenmannThe Ohio State University RSRonan SwordsOregon Health & Science University YHYing HuangFujian Medical University

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 1b/2 trial shows overall survival of 7.6 months in patients with acute myeloid leukemia, indicating potential efficacy of TP-0903 and decitabine.

Cite This Study

Eisenmann et al. (2025) studied this question.

synapsesocial.com/papers/689a02afe6551bb0af8cc102 https://doi.org/10.1158/2767-9764.29557244

View Full Paper

Ask AI

Bookmark

Implication

Phase 1b/2 trial shows overall survival of 7.6 months in patients with acute myeloid leukemia, indicating potential efficacy of TP-0903 and decitabine.

Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

Key Points

Discussion

Implication

Cite This Study

Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider